Star

Technology

LifeMatrix develops a unique bio-engineering technology to grow human replacement tissues in the laboratory as next generation implants for the treatment of cardiovascular diseases.

About us

LifeMatrix Technologies AG, is a pre-revenue, high-tech startup company spun out of the Institute for Regenerative Medicine  (University of Zurich).

Team

Our team combines world leading science in cardiovascular tissue engineering with in-depth entrepreneurial expertise in medical biomimetic device development. 

Press & News

VentureKick

2021

LifeMatrix wins CHF 150,000 to develop groundbreaking biomimetic implants designed to grow and regenerate with patients.

VentureKick

2021

LifeMatrix under Global Game Changers in the annual report by Venture Kick.

VentureLeaders

2020

LifeMatrix has been chosen by a jury of investors into the Swiss National Startup Team for Venture Leaders Life Sciences 2020 from over 60 applicants.

VentureKick

2020

LifeMatrix wins VentureKicks financial support.

Medical Device Network

2019

GlobalData: LifeMatrix set to disrupt cardiovascular implant market.

Diagnostic and Interventional Cardiology

2019

Tissue Engineering Will Disrupt Cardiovascular Implant Market.

Biba Medtech Insights

2019

Interview with Maximilian Emmert about the problems of transcatheter aortic valve implantation and how LifeMatrix could be the solution. 

University of Zurich

2019

Three Million Euros Awarded to Two UZH Researchers.

GlobalData

2018

Study uses simulations to predict cultured heart valve growth. 

Science Daily

2018

Computer-designed customized regenerative heart valves.

Blick

2018

Künstliche Herzklappe wächst mit dem Kind.

Neue Zürcher Zeitung

2017

Mitwachsende Prothesen für Babyherzen.

Biomimetic Solutions for Life

Award winning technology

Active in the field of biomimetic implants, LifeMatrix develops human cell derived, off-the-shelf available tissue engineered implants, which transform into living tissue after implantation and have the capacity to grow and regenerate with the patient.

 

The award winning technology is the result of multiple national and international research grants and is backed by more than 20 years of research with over 100 peer-reviewed publications.

 

Extensive preclinical (animal) studies demonstrated safety and efficacy and allow the technology to be translated in to clinical application.

Awards & Support